Original citation:

Permanent WRAP URL:
http://wrap.warwick.ac.uk/101551

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher’s statement:

A note on versions:
The version presented in WRAP is the published version or, version of record, and may be cited as it appears here.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk
A Randomized Trial of Early Endovenous Ablation in Venous Ulceration

Manjit S. Gohel, M.D., Francine Heatley, B.Sc., Xinxue Liu, Ph.D., Andrew Bradbury, M.D., Richard Bulbulia, M.D., Nicky Cullum, Ph.D., David M. Epstein, Ph.D., Isaac Nyamekye, M.D., Keith R. Poskitt, M.D., Sophie Renton, M.S., Jane Warwick, Ph.D., and Alun H. Davies, D.Sc., for the EVRA Trial Investigators*

BACKGROUND
Venous disease is the most common cause of leg ulceration. Although compression therapy improves venous ulcer healing, it does not treat the underlying causes of venous hypertension. Treatment of superficial venous reflux has been shown to reduce the rate of ulcer recurrence, but the effect of early endovenous ablation of superficial venous reflux on ulcer healing remains unclear.

METHODS
In a trial conducted at 20 centers in the United Kingdom, we randomly assigned 450 patients with venous leg ulcers to receive compression therapy and undergo early endovenous ablation of superficial venous reflux within 2 weeks after randomization (early-intervention group) or to receive compression therapy alone, with consideration of endovenous ablation deferred until after the ulcer was healed or until 6 months after randomization if the ulcer was unhealed (deferred-intervention group). The primary outcome was the time to ulcer healing. Secondary outcomes were the rate of ulcer healing at 24 weeks, the rate of ulcer recurrence, the length of time free from ulcers (ulcer-free time) during the first year after randomization, and patient-reported health-related quality of life.

RESULTS
Patient and clinical characteristics at baseline were similar in the two treatment groups. The time to ulcer healing was shorter in the early-intervention group than in the deferred-intervention group; more patients had healed ulcers with early intervention (hazard ratio for ulcer healing, 1.38; 95% confidence interval [CI], 1.13 to 1.68; P=0.001). The median time to ulcer healing was 56 days (95% CI, 49 to 66) in the early-intervention group and 82 days (95% CI, 69 to 92) in the deferred-intervention group. The rate of ulcer healing at 24 weeks was 85.6% in the early-intervention group and 76.3% in the deferred-intervention group. The median ulcer-free time during the first year after trial enrollment was 306 days (interquartile range, 240 to 328) in the early-intervention group and 278 days (interquartile range, 175 to 324) in the deferred-intervention group (P=0.002). The most common procedural complications of endovenous ablation were pain and deep-vein thrombosis.

CONCLUSIONS
Early endovenous ablation of superficial venous reflux resulted in faster healing of venous leg ulcers and more time free from ulcers than deferred endovenous ablation. (Funded by the National Institute for Health Research Health Technology Assessment Program; EVRA Current Controlled Trials number, ISRCTN02335796.)

* A complete list of the Early Venous Reflux Ablation (EVRA) trial investigators is provided in the Supplementary Appendix, available at NEJM.org.

Copyright © 2018 Massachusetts Medical Society.

ABSTRACT
A Randomized Trial of Early Endovenous Ablation in Venous Ulceration
From Cambridge University Hospitals NHS Foundation Trust, Cambridge (M.S.G.), the Department of Surgery and Cancer (M.S.G., F.H., A.H.D.) and Imperial Clinical Trials Unit (X.L., J.W.), Imperial College London, London, University of Birmingham, Birmingham (A.B.), Gloucestershire Hospitals NHS Foundation Trust, Gloucester (R.B., K.R.P.), the Medical Research Council Population Health Research Unit and the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford (R.B.), University of Manchester, Manchester (N.C.), Worcestershire Acute Hospitals NHS Trust, Worcester (I.N.), North West London Hospitals NHS Trust, Harrow (S.R.), and University of Warwick, Coventry (J.W.) — all in the United Kingdom; and the University of Granada, Granada, Spain (D.M.E.). Address reprint requests to Dr. Davies at the Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, Charing Cross Hospital, London W6 8RF, United Kingdom, or at a.h.davies@imperial.ac.uk.

This article was published on April 24, 2018, at NEJM.org.
DOI: 10.1056/NEJMoai1801214
Copyright © 2018 Massachusetts Medical Society.
VENOUS DISEASE IS THE MOST COMMON cause of leg ulceration, and compression therapy improves venous ulcer healing.1,2 Superficial venous reflux (varicose veins) is usually present in patients with venous leg ulcers.3 Endovenous interventions (ultrasound-guided foam sclerotherapy and thermal and nonthermal ablation) are effective, minimally invasive procedures that are used for the treatment of varicose veins and have largely replaced traditional surgery at many centers.4,6 In the Effect of Surgery and Compression on Healing and Recurrence (ESCHAR) study, superficial venous surgery in combination with compression therapy resulted in lower rates of recurrence of venous leg ulcers than compression therapy alone7,8 but was not associated with higher rates of ulcer healing. Observational studies have suggested that endovenous treatment of varicose veins — a treatment that may be particularly appropriate for the elderly population with venous leg ulcers — may improve ulcer healing.9-12 However, a lack of reliable evidence has resulted in weak support for endovenous ablation in current management guidelines.13,14 We performed the Early Venous Reflux Ablation (EVRA) trial to evaluate the role of early endovenous treatment of superficial venous reflux as an adjunct to compression therapy in patients with venous leg ulcers.

METHODS

TRIAL DESIGN AND OVERSIGHT

The EVRA trial was a multicenter, parallel-group, randomized, controlled trial that was funded by the National Institute for Health Research Health Technology Assessment Program. Details of the trial design and implementation are provided in the protocol, which is available with the full text of this article at NEJM.org.15 The trial was approved by the South West–Central Bristol Research Ethics Committee, and trial oversight was provided by an independent trial steering committee and an independent data and safety monitoring committee (the members of these committees are listed in the Supplementary Appendix, available at NEJM.org). Data were collected by trial staff at each recruitment center and were uploaded to the Web-based electronic data-capture system (InForm, Oracle Health Sciences). The authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the trial to the protocol.

TRIAL SETTING AND PATIENTS

From October 2013 through September 2016, patients with open venous leg ulcers were screened by personnel in the vascular surgery departments at 20 participating centers across the United Kingdom (Table S1 in the Supplementary Appendix). All the centers had established referral pathways for patients with venous leg ulcers and could provide early endovenous interventions. Patients were screened for eligibility by clinical assessment and duplex ultrasonography.

ELIGIBILITY CRITERIA

Patients older than 18 years of age were eligible for inclusion if they had an open venous leg ulcer that had been present for a period of between 6 weeks and 6 months, an ankle–brachial index of 0.8 or higher, and primary or recurrent superficial venous reflux that was deemed by the treating clinician to be clinically significant. Venous reflux was defined as a duration of retrograde flow of greater than 0.5 seconds in superficial veins and greater than 1 second in deep veins.16 The presence of deep venous reflux was recorded but was not an exclusion criterion. Patients were excluded if they were pregnant, were unable to adhere to compression therapy, had deep venous occlusive disease or any other condition precluding superficial venous ablation, had leg ulcers for which the cause was deemed to be nonvenous, or were thought to require skin grafting. In patients with venous leg ulcers in both legs, the leg with more severe disease (as determined by the patient) was designated as the “reference leg” and was included in the outcome analyses. Written informed consent was obtained from all participants.

RANDOMIZATION

Randomization sequences for each recruitment center were created with the use of randomly permuted blocks with two block sizes; the sequences had been prepared in advance by a trial statistician and uploaded to the data-capture system before recruitment. Treatment assignment was concealed as follows: each potential participant was enrolled in the data-capture system by staff at the local recruitment centers and, if eligibility was confirmed, was automatically assigned the next available entry in the appropriate randomization list. Participants were randomly assigned, in a 1:1 ratio, to receive compression therapy and undergo early endovenous ablation
Early Endovenous Ablation in Venous Ulceration

TRIAL INTERVENTIONS
Compression therapy was administered by trained community and hospital-based nursing teams according to the local standard of care. Multilayer elastic compression (two to four layers), short-stretch compression, and compression hosiery were all deemed to be acceptable. Among the patients assigned to the early-intervention group, the aim was for superficial venous reflux to be ablated within 2 weeks after randomization. Among the patients in the deferred-intervention group, an ablation procedure was considered after the ulcer had healed or at least 6 months after randomization if the ulcer had not healed. After the ulcer was healed, patients were offered elastic compression stockings according to local institutional policy. In both treatment groups, delivery of wound care and frequency of clinical follow-up were guided by local models of care.

Endovenous laser or radiofrequency ablation, ultrasound-guided foam sclerotherapy, or non-thermal, nontumescent methods of treatment (such as cyanoacrylate glue or mechanochemical ablation) were performed either alone or in combination. The treating clinical team determined the method and strategy of endovenous treatment. For all interventions, treating clinicians were asked to ablate the main refluxing truncal vein, treat to the lowest point of reflux where possible, and continue compression therapy immediately after endovenous treatment. Among the patients in the early-intervention group, duplex ultrasonography was to be performed 6 weeks after the intervention. Superficial venous reflux observed during follow-up was treated at the discretion of the treating clinician.

OUTCOME ASSESSMENTS
The primary outcome measure was the time to ulcer healing from the date of randomization through 12 months. The definition of ulcer healing used in the trial is provided in the Supplementary Appendix. Data from patients in whom no ulcer healing had been verified by 12 months after randomization were censored at the date of their last follow-up examination.

The secondary outcome measures were the rate of ulcer healing at 24 weeks, the rate of ulcer recurrence, the length of time free from ulcers (ulcer-free time) during the first year after randomization, and patient-reported health-related quality of life. Ulcer-free time was assessed only in patients who completed 1 year of follow-up. Clinical disease severity was assessed with the Venous Clinical Severity Score assessment tool (scores range from 0 to 30, with higher scores indicating more severe venous disease) at randomization and 6 weeks after randomization. A disease-specific quality-of-life assessment (the Aberdeen Varicose Vein Questionnaire; scores range from 0 to 100, with higher scores indicating worse health related to varicose veins) and two generic quality-of-life assessments (the EuroQol Group 5-Dimension 5-Level questionnaire [EQ-5D-5L; scores on the visual-analogue health scale range from 0 to 100 and scores on the descriptive health index range from 0 to 1, with higher scores indicating better quality of life] and the Medical Outcomes Study 36-Item Short-Form Health Survey [SF-36; scores range from 1 to 100, with higher scores indicating better quality of life]) were performed at randomization and at 6 weeks, 6 months, and 12 months after randomization (Tables S2 through S5 in the Supplementary Appendix). A health economic analysis was prespecified in the trial protocol, but the results are not reported in the current article.

STATISTICAL ANALYSIS
Assuming a 60% rate of ulcer healing at 24 weeks among the patients who received compression therapy alone and anticipating a 10% rate of loss to follow-up, we estimated that with 254 events (healed leg ulcers) among a total of 416 patients, the trial would have 90% power to detect a 15 percentage-point difference between the treatment groups in the healing rate at 24 weeks at a two-sided alpha level of 5% (log-rank test). To further allow for protocol violations and unexpected dropouts, the target sample size was 450 patients.

We tested the hypothesis that there would be no difference in the time to healing between the early-intervention group and the deferred-intervention group, first using an unadjusted Cox regression model with recruitment center as a random effect (prespecified primary analysis) and subsequently adjusting for the age of the patients, the length of time that the ulcer had been present (ulcer duration, also known as ulcer...
chronicity), and the size of the ulcers. Unadjusted rates of ulcer healing at 12 weeks and 24 weeks were calculated with the Kaplan-Meier method.  

Recurrence rates at 1 year were calculated as the percentage of patients in whom the ulcer had healed within 1 year after randomization but recurred before the end of the 1-year postrandomization follow-up period. Ulcer-free time was calculated as the number of days during the 1-year follow-up period on which the reference leg was fully healed. Ordered logistic regression (with ulcer-free time categorized in quartiles) was used to assess the effect of early versus deferred intervention on ulcer-free time. The difference between the two treatment groups in each measure of quality of life was assessed at each follow-up time point with the use of mixed models that were adjusted separately for participant age, ulcer size, and ulcer duration and included recruitment center as a random effect. All analyses were performed on an intention-to-treat basis with STATA software, version 14.2 (StataCorp), with statistical significance set at a two-sided alpha level of 5%.

**RESULTS**

**PATIENTS**

From October 2013 through September 2016, a total of 6555 patients were screened, 6105 were excluded, and 450 consented to participate in the EVRA trial and underwent randomization (Fig. 1). The most common reasons for ineligibility were an ulcer that had been present for more than 6 months (1772 patients), arterial disease (defined as an ankle–brachial index <0.8 or the presence of an arterial ulcer or both; 873 patients), or an ulcer that had already healed by the time of randomization (610 patients). The most common reason for potentially eligible patients not undergoing randomization was a treatment preference expressed by either the patient or the treating clinician.
Early Endovenous Ablation in Venous Ulceration

Baseline characteristics were similar in the early-intervention group and the deferred-intervention group (Table 1, and Table S6 in the Supplementary Appendix). Factors that are thought to affect the healing of venous leg ulcers, including ulcer duration, ulcer size, patient age, and...
The history of deep-vein thrombosis, were similar in the two treatment groups. The last 1-year patient follow-up examination was completed on September 28, 2017.

ENDOVENOUS INTERVENTIONS
Among the 224 patients in the early-intervention group, 203 (90.6%) underwent an endovenous procedure within 2 weeks after randomization (Table 2). One patient (0.4%) who was assigned to the deferred-intervention group but was mistakenly thought to be in the early-intervention group underwent an endovenous procedure within 2 weeks after randomization. Among the 105 patients in the deferred-intervention group who underwent an endovenous procedure within 6 months after randomization, 6 (5.7%) were treated before the ulcer had healed, including the 1 patient who underwent an endovenous procedure within 2 weeks after randomization in error, 3 patients who had clinical deterioration of the ulcer, and 2 patients who were unwilling to continue the deferred-intervention strategy and requested intervention. A total of 218 of 224 patients (97.3%) in the early-intervention group and 171 of 226 patients (75.7%) in the deferred-intervention group underwent an endovenous intervention within 1 year after randomization.

Among the 389 patients who underwent an endovenous intervention in the trial, 472 procedures were performed within 1 year after randomization (Table S7 in the Supplementary Appendix). A total of 218 of 224 patients (97.3%) in the early-intervention group and 171 of 226 patients (75.7%) in the deferred-intervention group underwent an endovenous intervention within 1 year after randomization.

The time to ulcer healing was shorter in the early-intervention group than in the deferred-intervention group; more patients had healed ulcers with early intervention (hazard ratio for ulcer healing, 1.38; 95% confidence interval [CI], 1.13 to 1.68; P = 0.001) (Fig. 2). The median time to ulcer healing was 56 days (95% CI, 49 to 66) in the early-intervention group and 82 days (95% CI, 69 to 92) in the deferred-intervention group.

### Table 2. Timing and Type of Endovenous Intervention.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Early Intervention (N = 224)</th>
<th>Deferred Intervention* (N = 226)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. (%)</td>
<td>no. (%)</td>
<td>no. (%)</td>
</tr>
<tr>
<td><strong>Timing of endovenous treatment after randomization†</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 2 wk</td>
<td>203 (90.6)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Before ulcer healing</td>
<td>200 (89.3)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>After ulcer healing</td>
<td>3 (1.3)</td>
<td>0</td>
</tr>
<tr>
<td>Between 2 and 4 wk</td>
<td>9 (4.0)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Before ulcer healing</td>
<td>9 (4.0)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>After ulcer healing</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Between 4 wk and 6 mo</td>
<td>6 (2.7)</td>
<td>103 (45.6)</td>
</tr>
<tr>
<td>Before ulcer healing</td>
<td>4 (1.8)</td>
<td>4 (1.8)</td>
</tr>
<tr>
<td>After ulcer healing</td>
<td>2 (0.9)</td>
<td>99 (43.8)</td>
</tr>
<tr>
<td>After 6 mo</td>
<td>0</td>
<td>66 (29.2)</td>
</tr>
<tr>
<td>Before ulcer healing</td>
<td>0</td>
<td>19 (8.4)</td>
</tr>
<tr>
<td>After ulcer healing</td>
<td>0</td>
<td>47 (20.8)</td>
</tr>
<tr>
<td>No treatment</td>
<td>6 (2.7)</td>
<td>55 (24.3)</td>
</tr>
<tr>
<td><strong>Type of endovenous intervention</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endothermal ablation only§</td>
<td>71 (31.7)</td>
<td>54 (23.9)</td>
</tr>
<tr>
<td>Foam sclerotherapy only¶</td>
<td>111 (49.6)</td>
<td>100 (44.2)</td>
</tr>
<tr>
<td>Mechanocemical ablation only</td>
<td>5 (2.2)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Endothermal ablation and foam sclerotherapy§¶</td>
<td>27 (12.1)</td>
<td>16 (7.1)</td>
</tr>
<tr>
<td>Mechanocemical ablation and foam sclerotherapy¶</td>
<td>3 (1.3)</td>
<td>0</td>
</tr>
<tr>
<td>Abandoned treatment‖</td>
<td>1 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td>No treatment</td>
<td>6 (2.7)</td>
<td>55 (24.3)</td>
</tr>
</tbody>
</table>

* Up to 6 months after randomization, the intervention was performed before ulcer healing in 6 patients in the deferred-intervention group: 3 patients had clinical deterioration of the ulcer, 2 patients were unwilling to continue the deferred-intervention strategy and requested intervention, and 1 patient was treated early in error. After 6 months, the intervention was performed before ulcer healing in 19 patients, as decided by the treating clinical team.
† The timing is reported for the first endovenous intervention only. The timing of any additional intervention was left to the discretion of the treating clinician.
‡ Among the 55 patients (24.3%) in the deferred-intervention group who did not receive treatment by 1 year after randomization, the ulcer had healed in 27 and had not healed in 9 (the reasons for not undergoing endovenous treatment were not recorded for these 9 patients); among the remaining 19 patients, 7 had died, 7 had withdrawn from the trial, and 5 were lost to follow-up. Among the 27 patients with healed ulcers, 16 declined intervention, 3 were no longer deemed to be suitable for intervention (as determined by the treating clinician), and 6 were on the waiting list for intervention and may have been treated after 12 months; the reason for not receiving treatment was unclear in 2 patients.
§ Endovenous thermal ablation procedures included laser and radiofrequency ablation.
¶ Ultrasound-guided foam sclerotherapy to treat tributary veins or subulcer venous plexus was performed according to the standard technique of the treating clinician.
‖ “Abandoned” indicates that the procedure could not be completed because of the inability to cannulate the vein to be treated.

PRIMARY OUTCOME
The time to ulcer healing was shorter in the early-intervention group than in the deferred-intervention group; more patients had healed ulcers with early intervention (hazard ratio for ulcer healing, 1.38; 95% confidence interval [CI], 1.13 to 1.68; P = 0.001) (Fig. 2). The median time to ulcer healing was 56 days (95% CI, 49 to 66) in the early-intervention group and 82 days (95% CI, 69 to 92) in the deferred-intervention group.
After adjustment for patient age, ulcer size, ulcer duration, and recruitment center, the results were consistent, with quicker ulcer healing in the early-intervention group than in the deferred-intervention group (hazard ratio, 1.42; 95% CI, 1.16 to 1.73; P=0.001).

SECONDARY OUTCOMES
The unadjusted Kaplan–Meier time-to-event rate of ulcer healing was higher in the early-intervention group than in the deferred-intervention group at 24 weeks (85.6% [95% CI, 80.6 to 89.8] vs. 76.3% [95% CI, 70.5 to 81.7]). In a post hoc analysis, the rates of ulcer healing at 12 weeks were 63.5% (95% CI, 57.2 to 69.8) in the early-intervention group and 51.6% (95% CI, 45.2 to 58.3) in the deferred-intervention group. Among the 450 patients who underwent randomization, 404 (89.7%) had healed ulcers within 1 year after randomization (210 of 224 [93.8%] in the early-intervention group and 194 of 226 [85.8%] in the deferred-intervention group). The between-group difference in healing rates at 1 year was 8.0 percentage points (95% CI, 2.3 to 13.5).

Among the 404 patients whose ulcers had healed within 1 year after randomization, the rate of ulcer recurrence before the end of the 1-year postrandomization follow-up period was 11.4% (24 of 210 patients) in the early-intervention group and 16.5% (32 of 194 patients) in the deferred-intervention group. The total length of follow-up after ulcer healing was 156.5 person-years in the early-intervention group and 139.7 person-years in the deferred-intervention group; the rate of ulcer recurrence was lower in the early-intervention group than in the deferred-intervention group (hazard ratio of being in a higher quartile of ulcer-free time, 1.54; 95% CI, 1.07 to 2.21; P=0.02). Mean (±SD) scores on the Venous Clinical Severity Score assessment tool did not differ significantly between the two treatment groups at randomization (15.8±3.3 in the early-intervention group and 15.7±3.1 in the deferred-intervention group). At 6 weeks, scores on the Venous Clinical Severity Score assessment tool were 10.5±4.7 in the early-intervention group and 12.6±4.4 in the deferred-intervention group.

Quality-of-life outcomes are summarized in Table 3, and in Tables S8 (SF-36 domain scores) and S9 (includes multiple imputation of missing values) in the Supplementary Appendix. At baseline, scores on the Aberdeen Varicose Vein Questionnaire, EQ-5D-5L, and SF-36 were similar in the early-intervention group and the deferred-intervention group. There was no clear difference in Aberdeen Varicose Vein Questionnaire scores between the treatment groups over the follow-up period, although scores were generally lower (indicating better disease-specific quality of life) in the early-intervention group than in the deferred-intervention group. Similarly, there was no clear difference between the treatment groups in the EQ-5D-5L index value during the follow-up period. Observed differences were not deemed to be significant when adjustment was made for multiple testing.

A total of 163 protocol deviations were recorded in the treatment groups, the majority of which were due to late or missed follow-up ap-
The most common procedural complications of endovenous ablation were pain and deep-vein thrombosis. Summaries of protocol deviations and procedural complications of endovenous ablation and the results of prespecified subgroup analyses based on baseline character-

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Early Intervention</th>
<th>Deferred Intervention</th>
<th>Between-Group Difference in Score (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
<td>Score</td>
<td>No. of Patients</td>
</tr>
<tr>
<td>Aberdeen Varicose Vein Questionnaire‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>200</td>
<td>44.1±9.0</td>
<td>192</td>
</tr>
<tr>
<td>6 wk</td>
<td>176</td>
<td>39.4±10.2</td>
<td>170</td>
</tr>
<tr>
<td>6 mo</td>
<td>139</td>
<td>34.6±9.4</td>
<td>140</td>
</tr>
<tr>
<td>12 mo</td>
<td>127</td>
<td>32.4±8.3</td>
<td>130</td>
</tr>
<tr>
<td>EQ-SD-5L health scale§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>222</td>
<td>70.2±17.7</td>
<td>222</td>
</tr>
<tr>
<td>6 wk</td>
<td>212</td>
<td>72.7±18.6</td>
<td>205</td>
</tr>
<tr>
<td>6 mo</td>
<td>185</td>
<td>74.1±15.8</td>
<td>193</td>
</tr>
<tr>
<td>12 mo</td>
<td>183</td>
<td>74.8±16.9</td>
<td>184</td>
</tr>
<tr>
<td>EQ-SD-5L health index¶</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>222</td>
<td>0.73±0.2</td>
<td>226</td>
</tr>
<tr>
<td>6 wk</td>
<td>211</td>
<td>0.79±0.2</td>
<td>208</td>
</tr>
<tr>
<td>6 mo</td>
<td>186</td>
<td>0.81±0.2</td>
<td>192</td>
</tr>
<tr>
<td>12 mo</td>
<td>184</td>
<td>0.83±0.2</td>
<td>182</td>
</tr>
<tr>
<td>SF-36 Physical Component Summary‖</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>222</td>
<td>38.5±9.9</td>
<td>223</td>
</tr>
<tr>
<td>6 wk</td>
<td>212</td>
<td>40.4±10.2</td>
<td>207</td>
</tr>
<tr>
<td>6 mo</td>
<td>187</td>
<td>41.5±11.5</td>
<td>193</td>
</tr>
<tr>
<td>12 mo</td>
<td>181</td>
<td>42.1±11.6</td>
<td>178</td>
</tr>
<tr>
<td>SF-36 Mental Component Summary‖</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>222</td>
<td>49.2±10.9</td>
<td>223</td>
</tr>
<tr>
<td>6 wk</td>
<td>212</td>
<td>51.1±10.4</td>
<td>207</td>
</tr>
<tr>
<td>6 mo</td>
<td>187</td>
<td>52.2±9.8</td>
<td>193</td>
</tr>
<tr>
<td>12 mo</td>
<td>181</td>
<td>51.6±9.5</td>
<td>178</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD.
† The between-group differences were estimated by a mixed model that adjusted for time, age, ulcer size, and ulcer duration as fixed effects and recruitment center as a random effect; the deferred-intervention group was the reference group. The widths of the confidence intervals were not adjusted for multiple comparisons and should not be used for formal inference.
‡ Scores on the Aberdeen Varicose Vein Questionnaire range from 0 to 100, with higher scores indicating worse health related to varicose veins.
§ Scores on the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-SD-5L) health scale (a visual-analogue scale) range from 0 to 100, with higher scores indicating better health.
¶ Score on the EQ-SD-5L health index range from 0 to 1, with higher scores indicating better health. The EQ-SD-5L health index was calculated with the value set for England.21
‖ Scores on the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Physical Component Summary and Mental Component Summary range from 1 to 100, with higher scores indicating better quality of life.
DISCUSSION

This multicenter, pragmatic, randomized trial showed that early endovenous ablation of superficial venous reflux as an adjunct to compression therapy was associated with a significantly shorter time to healing of venous leg ulcers than compression therapy alone. Patients assigned to the early-intervention group also had longer ulcer-free time during the first year after randomization.

Previous studies have also shown a benefit of superficial venous intervention in patients with venous leg ulcers. The ESCHAR study showed that the rate of ulcer recurrence was lower with superficial venous surgery as an adjunct to compression therapy than with compression therapy alone,7,8 and for this reason, the treatment of superficial venous reflux is recommended in international guidelines for the management of venous ulcers.13 However, worldwide, many patients with venous leg ulcers are not assessed or treated for superficial venous reflux, possibly because of the perception that treatment for varicose veins does not improve ulcer healing.13,22

In the current trial, we found that faster ulcer healing can be attained if an endovenous intervention is performed promptly. This benefit was observed despite the provision of high-quality compression therapy, which might explain the good healing rates observed in both treatment groups. Such effective compression therapy is probably not commonplace outside randomized trials, which may help explain the much slower healing times seen in the “real world.”23,24 Accordingly, the improvement in ulcer healing with early endovenous intervention is likely to be greater in clinical practice than was observed in this trial. Because endovenous intervention is usually performed as a single procedure, the clinical benefits are likely to be less dependent on ongoing patient adherence than they would be with compression therapy.

Pathways of care for leg ulcers, in general, do not include a provision for early assessment and treatment of superficial venous reflux.25 The lack of standardized models of care for leg ulcers and the involvement of a range of specialists may contribute to the inconsistent care delivered.

Although a benefit of endovenous intervention was observed in the current trial, the best method of ablation among those currently available remains unclear. In this pragmatic trial, treating clinicians were permitted to use the method of treatment for superficial venous reflux that they deemed to be most appropriate for the patients in their center. Ultrasound-guided foam sclerotherapy was the most common method of treatment used, which probably reflects the versatility and acceptability of this minimally invasive procedure. Results of large randomized studies have suggested that the rate of technical success (i.e., complete venous occlusion) may be lower with foam sclerotherapy than with endovenous thermal ablation.5,6 Whether this difference in the rate of complete venous occlusion will result in differing rates of ulcer recurrence in the medium or long term remains to be seen.

Our trial has several limitations. First, although all the recruitment centers had an established pathway of care for leg ulcers, considerable variations existed among centers, the most notable of which was the choice of endovenous treatment method. All treating clinicians were asked to abide by standardized intervention principles, and by stratifying the findings according to center, we attempted to ensure that any variations were equally distributed across the two treatment groups. Second, we screened more than 6500 patients to reach our target sample size of 450. Patients were often not eligible for inclusion in the trial because the ulcer had been present for longer than 6 months or had already healed by the time of randomization. This probably reflects failures in the referral pathways from primary care teams or wound-care centers to the vascular center. Third, variations were noted in the superficial veins that were refluxing and the presence and extent of deep venous reflux.25-27 Finally, follow-up duplex ultrasonography at 6 weeks after the intervention was required only in the early-intervention group; this could have led to more repeat procedures and a higher rate of
procedural success in that group than in the deferred-intervention group.

In conclusion, this multicenter, randomized trial showed that early endovenous ablation of superficial venous reflux as an adjunct to compression therapy was associated with a shorter time to healing of venous leg ulcers than compression therapy alone.

The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research (NIHR), or the Department of Health.

Supported by a grant from the NIHR Health Technology Assessment Program (project number 11/12/9197) (to Drs. Davies, Gohel, Bradbury, Bulbulia, Cullum, Epstein, Poskitt, and Warwick). Infrastructure support was provided by the NIHR Imperial Biomedical Research Centre.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Tijun Lee (research associate, University of Warwick) for assistance with data cleaning; Rahul Velineni and Chen Liu for core laboratory data activity; members of the Imperial Clinical Trials Unit (Rebecca Lawton [trial manager], Claire Smith, Hilda Tsang, Hema Collappen, and Natalia Klimowska-Nassar [operation managers], Amanda Bravery, Kayode Disu, and Nayan Das [InForm database team], and Ginny Picot [quality assurance] for trial infrastructure support; and Bruce L. Greaves, who was an active member of the trial steering committee throughout the study.

REFERENCES


Copyright © 2018 Massachusetts Medical Society.